← back to search

Daniela S. Thommen

The Netherlands Cancer Institute · NL
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, and Immune Cell Function and Interaction.
h-index
26
citations
8,098
works
203
NIH funding
primary concept
Medicine
email

Recent publications

Guidelines for T cell nomenclature
Nature reviews. Immunology 2025cited by 26position: middledoi
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial
Nature Medicine 2025cited by 4position: middledoi
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
npj Breast Cancer 2024cited by 17position: middledoi
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Nature Cancer 2023cited by 59position: middledoi
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Nature Cancer 2023cited by 2position: middledoi
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
Science Translational Medicine 2022cited by 52position: middledoi
Single-cell analysis of regions of interest (SCARI) using a photosensitive tag
Nature Chemical Biology 2021cited by 18position: middledoi
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research
Cancer Immunology Research 2021cited by 1position: middledoi
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Journal of Clinical Investigation 2018cited by 301position: middledoi
Trastuzumab emtansine (T-DM1) renders HER2 <sup>+</sup> breast cancer highly susceptible to CTLA-4/PD-1 blockade
Science Translational Medicine 2015cited by 332position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael von Bergwelt‐Baildon · Helmholtz Association of German Research Centres2 papers (2015–2018)Alfred Zippelius · University of Basel2 papers (2015–2018)Oleg Gluz · Centrum für Integrierte Onkologie1 papers (2015–2015)Matthias Christgen · The University of Texas MD Anderson Cancer Center1 papers (2015–2015)Kea Martin · Novartis (Switzerland)1 papers (2015–2015) · 1 papers (2015–2015) · 1 papers (2021–2021)Irene L. M. Reijers · Dutch Cancer Society1 papers (2022–2022)Mireille Toebes · The Netherlands Cancer Institute1 papers (2021–2021)Nadia Harbeck · Universität Bayern1 papers (2015–2015)Christopher I. Amos · UNM Comprehensive Cancer Center1 papers (2018–2018)Eyal David · Weizmann Institute of Science1 papers (2021–2021)Judith M. Versluis · The Netherlands Cancer Institute1 papers (2022–2022)Kayluz Frias Boligan · Université du Québec à Montréal1 papers (2018–2018)Heinz Läubli · University of Basel1 papers (2018–2018)Yaniv Lubling · University of Cambridge1 papers (2021–2021) · 1 papers (2022–2022)Ajit Varki · University of California San Diego1 papers (2018–2018) · 1 papers (2021–2021)Alexandar Tzankov · University Hospital of Basel1 papers (2018–2018)